kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system.
paper
Cited
Public
Unavailable
- Authors
- Simonin, F; GavΓ©riaux-Ruff, C; Befort, K; Matthes, H; Lannes, B; Micheletti, G; MattΓ©i, M G; Charron, G; Bloch, B; Kieffer, B
- Year
- 1995
- Journal
- Proceedings of the National Academy of Sciences of the United States of America
- PMID
- 7624359
- DOI
- 10.1073/pnas.92.15.7006
- PMCID
- PMC41460
Using the mouse delta-opioid receptor cDNA as a probe, we have isolated genomic clones encoding the human mu- and kappa-opioid receptor genes. Their organization appears similar to that of the human delta receptor gene, with exon-intron boundaries located after putative transmembrane domains 1 and 4. The kappa gene was mapped at position q11-12 in human chromosome 8. A full-length cDNA encoding the human kappa-opioid receptor has been isolated. The cloned receptor expressed in COS cells presents a typical kappa 1 pharmacological profile and is negatively coupled to adenylate cyclase. The expression of kappa-opioid receptor mRNA in human brain, as estimated by reverse transcription-polymerase chain reaction, is consistent with the involvement of kappa-opioid receptors in pain perception, neuroendocrine physiology, affective behavior, and cognition. In situ hybridization studies performed on human fetal spinal cord demonstrate the presence of the transcript specifically in lamina II of the dorsal horn. Some divergences in structural, pharmacological, and anatomical properties are noted between the cloned human and rodent receptors.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Kappa opioid receptor control of motivated behavior revisited. | Farahbakhsh ZZ et al. | β | 2026 | β |
| Baicalein isolated from <i>Oroxylum indicum</i> acts as a potent Β΅- and ΞΊ-opioid receptor antagonist agent via the reversal of agonist-mediated cAMP inhibition. | Singh K et al. | β | 2025 | β |
| Effects of Biased Analogues of the Kappa Opioid Receptor Agonist, U50,488, in Preclinical Models of Pain and Side Effects. | van de Wetering R et al. | β | 2025 | β |
| <i>De novo</i> generation of dual-target compounds using artificial intelligence. | Yasuda K et al. | β | 2025 | β |
| Intestinal immunoglobulins under microbial dysbiosis: implications in opioid-induced microbial dysbiosis. | Vitari N et al. | β | 2025 | β |
| Opioid receptor signaling throughout ontogeny: Shaping neural and behavioral trajectories. | Spodnick MB et al. | β | 2025 | β |
| ΞΊ-Opioid Receptor Agonists as Robust Pain-Modulating Agents: Mechanisms and Therapeutic Potential in Pain Modulation. | GarcΓa-DomΓnguez M | β | 2025 | β |
| ΞΊ-opioid receptor: from analgesic target to neuroimmune hub. | Tan Q et al. | β | 2025 | β |
| Interactions Between Endogenous Opioids and the Immune System. | Du W | β | 2024 | β |
| Limitations and potential of ΞΊOR biased agonists for pain and itch management. | El Daibani A et al. | β | 2024 | β |
| Preclinical Models of Attention Deficit Hyperactivity Disorder: Neurobiology, Drug Discovery, and Beyond. | McCarthy DM et al. | β | 2024 | β |
| Predicting therapeutic and side effects from drug binding affinities to human proteome structures. | Sawada R et al. | β | 2024 | β |
| Semisynthetic guanidino lipoglycopeptides with potent in vitro and in vivo antibacterial activity. | van Groesen E et al. | β | 2024 | β |
| Cocaine self-administration augments kappa opioid receptor system-mediated inhibition of dopamine activity in the mesolimbic dopamine system. | Estave PM et al. | β | 2023 | β |
| The role of opioid receptors in modulating Alzheimer's Disease. | Tanguturi P et al. | β | 2023 | β |
| Biased Ligands at the Kappa Opioid Receptor: Fine-Tuning Receptor Pharmacology. | Brust TF | β | 2022 | β |
| Fundamentals of the Dynorphins/Kappa Opioid Receptor System: From Distribution to Signaling and Function. | Cahill C et al. | β | 2022 | β |
| Identification and Validation of Inflammatory Response-Related Gene Signatures to Predict the Prognosis of Neuroblastoma. | Song J et al. | β | 2022 | β |
| Opioids in cancer: The ΞΊβopioid receptor (Review). | Zhou Q et al. | β | 2022 | β |
| Pain-induced alterations in the dynorphinergic system within the mesocorticolimbic pathway: Implication for alcohol addiction. | Lorente JD et al. | β | 2022 | β |
| Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands. | Sturaro C et al. | β | 2022 | β |
| Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates. | Ko MC et al. | β | 2022 | β |
| The apelin/APJ signaling system and cytoprotection: Role of its cross-talk with kappa opioid receptor. | Ilaghi M et al. | β | 2022 | β |
| The Kappa Opioid Receptor System in Temporal Lobe Epilepsy. | Zangrandi L et al. | β | 2022 | β |
| The Role of the Endogenous Opioid System in the Vocal Behavior of Songbirds and Its Possible Role in Vocal Learning. | Singh UA et al. | β | 2022 | β |
| Adult-Attention Deficit Hyperactive Disorder Symptoms Seem Not to Influence the Outcome of an Enhanced Agonist Opioid Treatment: A 30-Year Follow-Up. | Maremmani AGI et al. | β | 2021 | β |
| Contingent Tunes of Neurochemical Ensembles in the Norm and Pathology: Can We See the Patterns? | Trofimova I | β | 2021 | β |
| Functional Constructivism Approach to Multilevel Nature of Bio-Behavioral Diversity. | Trofimova I | β | 2021 | β |
| Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine. | Cameron CM et al. | β | 2021 | β |
| Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease. | Denny L et al. | β | 2021 | β |
| Pituitary neuropeptides and B lymphocyte function. | Benko AL et al. | β | 2021 | β |
| ΞΊβopioid receptor agonist U50488H attenuates postoperative cognitive dysfunction of cardiopulmonary bypass rats through the PI3K/AKT/Nrf2/HOβ1 pathway. | Fan J et al. | β | 2021 | β |
| Opioid Receptors in Immune and Glial Cells-Implications for Pain Control. | Machelska H et al. | β | 2020 | β |
| Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). | Pizzagalli DA et al. | β | 2020 | β |
| Strategies for Developing <i>ΞΊ</i> Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects. | Paton KF et al. | β | 2020 | β |
| A Survey of Molecular Imaging of Opioid Receptors. | Cumming P et al. | β | 2019 | β |
| Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). | Guerrero M et al. | β | 2019 | β |
| Development and In Vivo Evaluation of a ΞΊ-Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics. | Li S et al. | β | 2019 | β |
| Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging. | Placzek MS et al. | β | 2019 | β |
| Members of the same pharmacological family are not alike: Different opioids, different consequences, hope for the opioid crisis? | Emery MA et al. | β | 2019 | β |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | β | 2019 | β |
| Novel Drug-Like Somatostatin Receptor 4 Agonists are Potential Analgesics for Neuropathic Pain. | KΓ‘ntΓ‘s B et al. | β | 2019 | β |
| Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. | Matuskey D et al. | β | 2019 | β |
| Structure and dynamics of dynorphin peptide and its receptor. | FerrΓ© G et al. | β | 2019 | β |
| Targeting opioid dysregulation in depression for the development of novel therapeutics. | Browne CA et al. | β | 2019 | β |
| Advances in Achieving Opioid Analgesia Without Side Effects. | Machelska H et al. | β | 2018 | β |
| Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol. | Anderson RI et al. | β | 2018 | β |
| Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions. | Butelman ER et al. | β | 2018 | β |
| Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans. | Bershad AK et al. | β | 2018 | β |
| G protein signaling-biased agonism at the ΞΊ-opioid receptor is maintained in striatal neurons. | Ho JH et al. | β | 2018 | β |
| Role of dorsal hippocampus ΞΊ opioid receptors in contextual aversive memory consolidation in rats. | Vanz F et al. | β | 2018 | β |
| Stress-induced modulation of pain: Role of the endogenous opioid system. | Ferdousi M et al. | β | 2018 | β |
| Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol. | Anderson RI et al. | β | 2017 | β |
| Benefits of Distinguishing between Physical and Social-Verbal Aspects of Behavior: An Example of Generalized Anxiety. | Trofimova I et al. | β | 2016 | β |
| Dynorphin A analogs for the treatment of chronic neuropathic pain. | Hall SM et al. | β | 2016 | β |
| Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans. | Maqueda AE et al. | β | 2016 | β |
| Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? | Albert-Vartanian A et al. | β | 2016 | β |
| Activation of ΞΊ-opioid receptor by U50,488H improves vascular dysfunction in streptozotocin-induced diabetic rats. | Zhou X et al. | β | 2015 | β |
| Biased agonism at kappa opioid receptors: Implication in pain and mood disorders. | Dogra S et al. | β | 2015 | β |
| Bioinformatics and evolution of vertebrate nociceptin and opioid receptors. | Stevens CW | β | 2015 | β |
| Drug effects on responses to emotional facial expressions: recent findings. | Miller MA et al. | β | 2015 | β |
| Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. | Befort K | β | 2015 | β |
| Investigational drugs under development for the treatment of PTSD. | Ragen BJ et al. | β | 2015 | β |
| Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies. | Schmitt S et al. | β | 2015 | β |
| Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans. | Bershad AK et al. | β | 2015 | β |
| Opioid receptors: methods for detection and their modes of actions in the eye. | Husain S | β | 2015 | β |
| Predicted structures for kappa opioid G-protein coupled receptor bound to selective agonists. | Li Q et al. | β | 2015 | β |
| Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. | Butelman ER et al. | β | 2015 | β |
| Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans. | Maqueda AE et al. | β | 2015 | β |
| Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction. | Chartoff EH et al. | β | 2015 | β |
| 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse. | Charbogne P et al. | β | 2014 | β |
| An Improved Antagonist Radiotracer for the ΞΊ-Opioid Receptor: Synthesis and Characterization of (11)C-LY2459989. | Zheng MQ et al. | β | 2014 | β |
| Does the kappa opioid receptor system contribute to pain aversion? | Cahill CM et al. | β | 2014 | β |
| Kappa Opioid Receptor Agonist and Brain Ischemia. | Chunhua C et al. | β | 2014 | β |
| Kinetic modeling of (11)C-LY2795050, a novel antagonist radiotracer for PET imaging of the kappa opioid receptor in humans. | Naganawa M et al. | β | 2014 | β |
| Salvinorin A analogs and other ΞΊ-opioid receptor compounds as treatments for cocaine abuse. | Kivell BM et al. | β | 2014 | β |
| The association of genetic polymorphisms in the ΞΊ-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance. | Wang SC et al. | β | 2014 | β |
| The role of the opioid system in alcohol dependence. | Nutt DJ | β | 2014 | β |
| Development of ΞΊ opioid receptor antagonists. | Carroll FI et al. | β | 2013 | β |
| Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment. | Bailey CR et al. | β | 2013 | β |
| Role of kappa-opioid receptors in stress and anxiety-related behavior. | Van't Veer A et al. | β | 2013 | β |
| Synthesis and evaluation of 11C-LY2795050 as a ΞΊ-opioid receptor antagonist radiotracer for PET imaging. | Zheng MQ et al. | β | 2013 | β |
| The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. | Alexander SP et al. | β | 2013 | β |
| Two families with normosmic congenital hypogonadotropic hypogonadism and biallelic mutations in KISS1R (KISS1 receptor): clinical evaluation and molecular characterization of a novel mutation. | Brioude F et al. | β | 2013 | β |
| OPRM1 and EGFR contribute to skin pigmentation differences between Indigenous Americans and Europeans. | Quillen EE et al. | β | 2012 | β |
| ΞΊ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. | Butelman ER et al. | β | 2012 | β |
| Endogenous ΞΌ-opioid peptides modulate immune response towards malignant melanoma. | Boehncke S et al. | β | 2011 | β |
| Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor. | Del Giudice MR et al. | β | 2011 | β |
| Synthesis, biological evaluation, and automated docking of constrained analogues of the opioid peptide H-Dmt-D-Ala-Phe-Gly-NHβ using the 4- or 5-methyl substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one scaffold. | De Wachter R et al. | β | 2011 | β |
| Transcriptional and epigenetic regulation of opioid receptor genes: present and future. | Wei LN et al. | β | 2011 | β |
| Evaluation of the kappa-opioid receptor-selective tracer [(11)C]GR103545 in awake rhesus macaques. | Schoultz BW et al. | β | 2010 | β |
| The role of kappa-opioid receptor activation in mediating antinociception and addiction. | Wang YH et al. | β | 2010 | β |
| 30 years of dynorphins--new insights on their functions in neuropsychiatric diseases. | Schwarzer C | β | 2009 | β |
| Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. | Ko MC et al. | β | 2009 | β |
| High-level production and characterization of a G-protein coupled receptor signaling complex. | Marino SF | β | 2009 | β |
| kappa-Opioid receptor signaling and brain reward function. | Bruijnzeel AW | β | 2009 | β |
| Synthesis and evaluation of a full-agonist orvinol for PET-imaging of opioid receptors: [11C]PEO. | Marton J et al. | β | 2009 | β |
| The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons. | Su X et al. | β | 2009 | β |
| The evolution of vertebrate opioid receptors. | Stevens CW | β | 2009 | β |
| Anatomical profiling of G protein-coupled receptor expression. | Regard JB et al. | β | 2008 | β |
| A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence. | Edenberg HJ et al. | β | 2008 | β |
| Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. | Cheng B et al. | β | 2008 | β |
| Developmental expression and distribution of opioid receptors in zebrafish. | Sanchez-Simon FM et al. | β | 2008 | β |
| The effects of pentazocine, a kappa agonist, in patients with mania. | Cohen BM et al. | β | 2008 | β |
| The opioidergic system: potential roles and therapeutic indications in the eye. | Husain S et al. | β | 2008 | β |
| Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. | Szarka LA et al. | β | 2007 | β |
| Up-regulation of delta-opioid receptors and kappa-opioid receptors in the skin of fibromyalgia patients. | Salemi S et al. | β | 2007 | β |
| Association of the kappa-opioid system with alcohol dependence. | Xuei X et al. | β | 2006 | β |
| New kappa opioid receptor from zebrafish Danio rerio. | Alvarez FA et al. | β | 2006 | β |
| Synthesis and evaluation as NOP ligands of some spiro[piperidine-4,2'(1'H)-quinazolin]-4'(3'H)-ones and spiro[piperidine-4,5'(6'H)-[1,2,4]triazolo[1,5-c]quinazolines]. | Mustazza C et al. | β | 2006 | β |
| Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. | Dortch-Carnes J et al. | β | 2005 | β |
| Detection of kappa and delta opioid receptors in skin--outside the nervous system. | Salemi S et al. | β | 2005 | β |
| Kappa opioid receptor is expressed in the rat cerebellar cortex. | HerrΓ‘ez-Baranda LA et al. | β | 2005 | β |
| Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. | Kreek MJ et al. | β | 2005 | β |
| The contribution of genetics to addiction therapy approaches. | Edenberg HJ et al. | β | 2005 | β |
| A new synthetic approach of N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide (JTC-801) and its analogues and their pharmacological evaluation as nociceptin receptor (NOP) antagonists. | Sestili I et al. | β | 2004 | β |
| Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA. | Kreek MJ et al. | β | 2004 | β |
| Exploring deltorphin II binding to the third extracellular loop of the delta-opioid receptor. | Fadhil I et al. | β | 2004 | β |
| FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity. | Vanderah TW et al. | β | 2004 | β |
| Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. | LΓΆtsch J et al. | β | 2004 | β |
| Inhibition of cell migration via G protein-coupled receptors to opioid peptides and angiotensin. | Entschladen F et al. | β | 2004 | β |
| Opioid receptors. | Waldhoer M et al. | β | 2004 | β |
| Peripheral kappa-opioid agonists for visceral pain. | RiviΓ¨re PJ | β | 2004 | β |
| Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic kappa-opioid agonists in rhesus monkeys. | Butelman ER et al. | β | 2004 | β |
| Recent advances in selective opioid receptor agonists and antagonists. | Eguchi M | β | 2004 | β |
| Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. | Yuferov V et al. | β | 2004 | β |
| Anti-analgesic activity of enterostatin (VPDPR) is mediated by corticosterone. | Takenaka Y et al. | β | 2003 | β |
| Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. | Delgado-Aros S et al. | β | 2003 | β |
| Expression and localization of opioid receptors in muscle satellite cells: no difference between fibromyalgia patients and healthy subjects. | Salemi S et al. | β | 2003 | β |
| Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys. | Ko MC et al. | β | 2003 | β |
| Opioid receptors on white blood cells: effect of HIV infection and methadone treatment. | Beck M et al. | β | 2002 | β |
| Visualizing preference of G protein-coupled receptor kinase 3 for the process of kappa-opioid receptor sequestration. | Schulz R et al. | β | 2002 | β |
| Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders. | Peckys D et al. | β | 2001 | β |
| Sex differences in opioid antinociception: kappa and 'mixed action' agonists. | Craft RM et al. | β | 2001 | β |
| Autoradiographic distribution of mu-, delta- and kappa 1-opioid stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in human frontal cortex and cerebellum. | Platzer S et al. | β | 2000 | β |
| Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. | Griffin G et al. | β | 2000 | β |
| kappa-Opioid receptor potentiates apoptosis via a phospholipase C pathway in the CNE2 human epithelial tumor cell line. | Diao CT et al. | β | 2000 | β |
| Molecular mechanisms and regulation of opioid receptor signaling. | Law PY et al. | β | 2000 | β |
| Opioid receptor and peptide gene polymorphisms: potential implications for addictions. | LaForge KS et al. | β | 2000 | β |
| Expression of delta, kappa and mu human opioid receptors in Escherichia coli and reconstitution of the high-affinity state for agonist with heterotrimeric G proteins. | Stanasila L et al. | β | 1999 | β |
| Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. | Peckys D et al. | β | 1999 | β |
| Expression of ZFOR1, a delta-opioid receptor, in the central nervous system of the zebrafish (Danio rerio). | Porteros A et al. | β | 1999 | β |
| Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys. | Ko MC et al. | β | 1999 | β |
| Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. | Becker JA et al. | β | 1999 | β |
| NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. | Mao J | β | 1999 | β |
| Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. | Ko MC et al. | β | 1998 | β |
| Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. | Peluso J et al. | β | 1998 | β |
| Kappa-opioid receptor binding varies inversely with tumor grade in human gliomas. | Pan EC et al. | β | 1998 | β |
| Opiate tolerance and dependence: receptors, G-proteins, and antiopiates. | Harrison LM et al. | β | 1998 | β |
| Structural features determining differential receptor regulation of neuronal Ca channels. | Simen AA et al. | β | 1998 | β |
| Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. | Gourlay GK | β | 1998 | β |
| Characterization of delta, kappa, and mu human opioid receptors overexpressed in baculovirus-infected insect cells. | Massotte D et al. | β | 1997 | β |
| Detection of opioid receptor mRNA by RT-PCR reveals alternative splicing for the delta- and kappa-opioid receptors. | GavΓ©riaux-Ruff C et al. | β | 1997 | β |
| Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. | Staley JK et al. | β | 1997 | β |
| Molecular cloning and pharmacological characterization of a new galanin receptor subtype. | Wang S et al. | β | 1997 | β |
| Opiate and cocaine addictions: challenge for pharmacotherapies. | Kreek MJ | β | 1997 | β |
| Taxol inhibits opioid binding on T47D human breast cancer cells. | Bakogeorgou E et al. | β | 1997 | β |
| Laminar distribution of the multiple opioid receptors in the human cerebral cortex. | Hiller JM et al. | β | 1996 | β |
| Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. | Kieffer BL | β | 1995 | β |